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Identity 
Other names: hsa-mir-200c, MIRN200C, mir-200c 
HGNC (Hugo): MIR200C 
Location: 12p13.31 
Local order: Based on Mapviewer Genes on 
Sequence, genes flanking MIRN200C oriented from 
centromere to telomere on 12q13.31 are: 
- ATN1; Atrophin 1, 12q13.31 
- U7; U7 small nuclear 1, 12q13.31 
- C12orf57; Chromosome 12 open reading frame 57, 
12q13.31 
- PTPN6; Protein tyrosine phosphatase, non-receptor 
type 6, 12q13.31 
- MIRN200C; microRNA 200c, 12q13.31 
- MIRN141; microRNA 141, 12q13.31 
- snoU89; small nucleolar RNA U89, 12q31.1 
- PHB2; Prohibitin 2, 12q31.1 
DNA/RNA 
Description 
miR-200c belongs to the miR-200 family, which 
consists of 5 members with two different chromosomal 
locations: miR-200c and miR-141 are located on 
chromosome 12p13 and miR-200a, miR-200b and 
miR-429 are located on 1p36. This family is frequently 
downregulated upon the progression of tumors and 
maps to fragile chromosomal regions. Members of this 
family are important regulators of epithelial-to-
mesenchymal transition (EMT) and metastasis. 
Transcription 
miRNAs are generally transcribed by RNA polymerase 
II. 
 
hsa-mir-200c (precursor miRNA) 
Accession: MI0000650 










No reported pseudogenes. 
 
A. Stem-loop structure of hsa-mir-200c (precursor miRNA). 
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B. The miR-200 family members. The human miR-200 family is located in two fragile chromosomal regions on 1p36.33 (200b, 200a and 
429) and 12p13.31 (200c and 141), respectively. It consists of two clusters based on seed sequence similarity: miR-200bc/429 (red) and 




microRNAs are not translated into amino acids. 
Mutations 
Note 




Loss of miR-200c expression was found to be 
associated with disease progression and poor outcome 
in 100 stage T1 bladder tumor patients (Wiklund et al., 
2011). 
Oncogenesis 
Deep sequencing of nine bladder urothelial carcinomas 
and matched normal urothelium revealed that the miR-
200c/141 cluster is upregulated in bladder cancer (Han 
et al., 2011). Consistently, a study comparing miRNA 
expression patterns by microarray in 27 invasive and 30 
superficial bladder tumors with 11 normal urothelia 
found that miR-200c was upregulated in bladder 
tumors compared to normal urothelium; however, 
expression of miR-200c was reduced in invasive 
compared to non-invasive tumors due to promoter 
hypermethylation (Wiklund et al., 2011). Furthermore, 
microarray miRNA analysis of 43 primary tumors (10 
colon, 10 bladder, 13 breast and 10 lung cancers) and 
matched lymph node metastases revealed that miR-
200c and other miR-200 family members are 
downregulated in metastases compared to primary 
tumors (Baffa et al., 2009). This suggests that while 
miR-200c may have oncogenic function in bladder 
cancer, it interferes with invasion and metastasis. 
Mechanistically, miR-200c has been implicated in the
regulation of epithelial-to-mesenchymal transition 
(EMT) in bladder cancer cells. A comparison of nine 
bladder cancer cell lines revealed a correlation betwe n  
high expression of miR-200c (and fellow miR-200 
family member miR-200b) and epithelial phenotype 
(Adam et al., 2009). The same study also reported that 
miR-200c expression reverses resistance to anti-EGFR 




A double-negative feedback loop between ZEB family 
transcription factors and the miR-200 family was 
shown to regulate EMT in different cell systems, 
including breast cancer cells (Burk et al., 2008). 
Moreover, expression of miR-200c was revealed to be 
activated by p53, resulting in induction of EMT in 
mammary epithelial cells upon loss of p53 (Chang et 
al., 2011). Loss of p53 was positively correlated with 
expression of ZEB1 and negatively correlated with 
expression of miR-200c and E-Cadherin in 106 breast 
tumor specimens. 
miRNA microarray analysis of 43 primary tumors (10 
colon, 10 bladder, 13 breast and 10 lung cancers) and 
matched lymph node metastases revealed that miR-
200c and other miR-200 family members are 
downregulated in metastases compared to primary 
tumors (Baffa et al., 2009). Moreover, miR-200c and 
other miR-200 family members were shown to be 
underexpressed in the aggressive claudin-low subtype 
of breast cancer, which displays an EMT-like gene 
expression signature (Herschkowitz et al., 2011). In 
contrast, luminal breast cancers, which have a more 
epithelial-like phenotype and a better clinical 
prognosis, express high levels of miR-200c 
(Bockmeyer et al., 2011). 
Re-expression of the miR-200 family in aggressive 
breast cancer cells was shown to inhibit experimental 
lung metastasis (Ahmad et al., 2011). In contrast, 
another study reported that miR-200c promotes 
colonization of breast cancer cells (Dykxhoorn et al., 
2009). In in vitro assays, miR-200c suppresses 
migration and invasion of breast cancer cells through 
various mechanisms, including targeting of 
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ZEB1/ZEB2, PLCG1, moesin and fibronectin (Korpal 
et al., 2008; Uhlmann et al., 2010; Howe et al., 2011). 
miR-200c also targets stem cell factors such as BMI1, 
and downregulation of miR-200c was shown to be 
characteristic of breast cancer stem cells (Shimono et 
al., 2009). Furthermore, miRNA microarray analysis 
revealed that miR-200c is downregulated in breast 
cancer cells with acquired resistance to cisplatin 
(Pogribny et al., 2010). 
Colorectal cancer 
Prognosis 
Kaplan-Meier survival analysis of 24 colorectal caner 
patients suggested that high expression of miR-200c 
was associated with decreased overall survival (Xi et 
al., 2006). 
Oncogenesis 
Analysis of miR-200c expression in 24 colorectal 
cancer biopsies and matched normal samples by qRT-
PCR revealed that miR-200c is overexpressed in 
colorectal tumors compared to normal tissue (Xi et al., 
2006). Furthermore, microarray miRNA analysis of 43 
primary tumors (10 colon, 10 bladder, 13 breast and 10 
lung cancers) and matched lymph node metastases 
revealed that miR-200c and other miR-200 family 
members are downregulated in metastases compared to 
primary tumors (Baffa et al., 2009). 
Endometrial cancer 
Disease 
Endometrial carcinoma; endometrial carcinosarcoma. 
Oncogenesis 
miRNA microarray analysis of four endometrial 
endometrioid carcinomas and four normal endometrial 
tissue samples showed that miR-200c and other miR-
200 family members were overexpressed in cancerous 
compared to normal tissue (Lee et al., 2011). Inhibition 
of miR-200c decreased the growth of endometrial 
carcinoma cells (Lee et al., 2011). In contrast, an 
analysis of miR-200c expression levels in five 
endometrial cancer and normal endometrial cell lines 
suggested that miR-200c is lower in cell lines derived 
from aggressive cancer compared to those derived from
less aggressive cancer or normal endometrial 
epithelium (Cochrane et al., 2009). Restoration of miR-
200c expression in aggressive endometrial cancer cells 
reduced their migration and invasion and increased 
their sensitivity to microtubule-targeting 
chemotherapeutic agents, at least in part through 
targeting TUBB3 (Cochrane et al., 2009; Cochrane et 
al., 2010; Howe et al., 2011). In a panel of 23 
endometrial carcinosarcomas, which are composed of 
mixed populations of epithelial-like and mesenchymal-
like cells, miR-200c and other miR-200 family 
members were found to be downregulated in the 
mesenchymal components of the tumors compared to 
the epithelial components (Castilla et al., 2011); this is  
consistent with the established role of the miR-200 




In a panel of 98 esophageal cancer patients treated wi h 
preoperative chemotherapy and surgery, expression of 
miR-200c was associated with shortened overall 
survival and poor response to chemotherapy, 
potentially through upregulation of the Akt signalig 
pathway (Hamano et al., 2011). 
Oncogenesis 
qRT-PCR analysis of miR-200 expression levels in 17 
patients with Barrett's esophagus and 20 patients with 
esophageal adenocarcinoma indicated that miR-200c is 
downregulated during cancer progression from normal 
epithelium through Barrett's esophagus to esophageal 
adenocarcinoma (Smith et al., 2011). In contrast, 
another study on 98 esophageal cancer patients treated 
with preoperative chemotherapy and surgery found that 
miR-200c was expressed at higher levels in the tumor 
than in normal tissue (Hamano et al., 2011). 
Germ cell tumors 
Disease 
Germinoma; yolk sac tumors. 
Oncogenesis 
Diagnosis. Microarray analysis of 25 germ cell tumors 
and subsequent validation by qRT-PCR in 10 
independent samples identified miR-200c as 
overexpressed in yolk sac tumors compared to 
germinoma (Murray et al., 2010). 
Head and neck cancer 
Disease 
Squamous cell carcinoma; spindle cell carcinoma. 
Oncogenesis 
miR-200c was significantly downregulated in a panel 
of 30 spindle cell carcinomas (which display a 
mesenchymal-like phenotype) compared to normal 
mucosa as determined by qRT-PC (Zidar et al., 2011). 
In contrast, expression levels of miR-200c in 30 




Diagnosis. Due to its low expression in liver compared 
to other tissues, miR-200c has been suggested as a 
biomarker to distinguish hepatocellular carcinoma from 
liver metastases (Barshack et al., 2010). 
miRNA microarray analysis of 92 primary 
hepatocellular carcinomas and 9 hepatocellular 
carcinoma cell lines identified miR-200c as a 
microRNA that is upregulated by p53 (Kim et al., 
2011). Increased expression of miR-200c results in 
downregulation of transcriptional repressors ZEB1  
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and ZEB2, suggesting a role for p53-mediated 
regulation of miR-200c in suppression of EMT. miR-
200c was reported to be underexpressed in benign liver 
tumors compared to hepatocellular carcinoma (Ladeiro 
et al., 2008); miR-200c levels were determined by 
qRT-PCR in two sets of tumors (first set: 18 benign 
tumors, 28 hepatocellular carcinomas; second set: 12 
benign tumors, 22 hepatocellular carcinomas). 
Lung cancer 
Prognosis 
qRT-PCR analysis of miR-200c expression levels in 70 
non-small cell lung cancer (NSCLC) patients revealed 
that high expression of miR-200c was associated with
reduced overall survival (Liu et al., 2011). 
Oncogenesis 
Treatment of immortalized human bronchial epithelial 
cells with tobacco carcinogens was shown to induce an 
EMT-like phenotype and stem-cell like properties 
(Tellez et al., 2011). Quantification of miRNA levels 
by qRT-PCR in combination with bisulfite sequencing 
and chromatin immunoprecipitation revealed that these 
changes are accompanied by epigenetic silencing of 
miR-200c and other EMT-regulating microRNAs, 
suggesting that loss of miR-200c contributes to 
transformation of lung epithelial cells. In contras, 
miRNA microarray analysis of six NSCLCs and 
matched adjacent normal tissue revealed that miR-200c 
is upregulated in NSCLC compared to healthy tissue 
(Liu et al., 2011). This finding was further validated in 
70 lung carcinomas and matched normal tissue by qRT-
PCR. 
Several studies have reported that miR-200c can 
repress invasion and metastasis of lung cancer cells. 
Firstly, low expression of miR-200c and other miR-200 
family members was associated with increased 
metastatic potential in a syngeneic mouse model of 
lung adenocarcinoma, and re-expression of miR-200 
family members in these cell lines prevented EMT and
metastasis (Gibbons et al., 2009). Secondly, miR-200c 
was shown to be downregulated by promoter 
hypermethylation in invasive NSCLC cell lines, and re-
expression of miR-200c reduced the invasive potential 
of these cell lines (Ceppi et al., 2010). Furthermore, 
microarray miRNA analysis of 43 primary tumors (10 
colon, 10 bladder, 13 breast and 10 lung cancers) and 
matched lymph node metastases revealed that miR-
200c and other miR-200 family members are 
downregulated in metastases compared to primary 
tumors (Baffa et al., 2009). Finally, low expression f 
miR-200c in 69 primary lung tumors was correlated 
with lymph node metastases (Ceppi et al., 2010). 
Mechanistically, the Notch ligand Jagged2 was shown 
to suppress expression of miR-200 family members, 
resulting in induction of EMT and increased metastatic 
potential (Yang et al., 2011). Moreover, miR-200c and 
fellow miR-200 family member miR-200b target 
VEGFR, which also contributes to invasion and 
metastasis (Roybal et al., 2011). 
Malignant pleural mesothelioma 
Oncogenesis 
Diagnosis. miR-200c has been proposed as a biomarker 
to distinguish malignant pleural mesothelioma from 
lung adenocarcinoma and lung metastases of other 
carcinomas. miRNA microarray expression profiling of 
10 lung adenocarcinomas and 15 mesotheliomas 
revealed that miR-200c is reduced in mesothelioma 
(Gee et al., 2010). This result was further confirmed by 
qRT-PCR in a set of 100 mesotheliomas and 32 lung 
adenocarcinomas. Similarly, microRNA microarray 
analysis of 7 malignant pleural mesotheliomas and 97 
carcinomas of various origins also identified miR-200c 
as underexpressed in mesotheliomas compared to the 
carcinoma samples, and differential expression levels 
of miR-200c and two other microRNAs could 
successfully be used to distinguish between malignant 
pleural mesothelioma and other types of cancer 
(Benjamin et al., 2010). 
Melanoma 
Oncogenesis 
Analysis of miR-200c expression levels in a panel of 
10 melanoma cell lines by qRT-PCR showed that miR-
200c is overexpressed in many of these cell lines 
compared to normal melanocytes (Elson-Schwab et al., 
2010). Overexpression of miR-200c in melanoma cell 
lines resulted in a shift towards amoeboid type of 
migration, possibly through targeting of MARCKS. 
Ovarian cancer 
Prognosis 
High expression of miR-200c was found to be 
correlated with decreased progression-free and overall 
survival in a panel of 20 serous ovarian cancer patients 
(Nam et al., 2008). In contrast, a study investigating 
microRNA expression profiles in a total of 144 patien s 
with epithelial ovarian cancer found that low 
expression of miR-200c was associated with increased 
progression-free and overall survival (Marchini et al., 
2011). Similarly, high expression of miR-200c was 
correlated with response to chemotherapy and 
decreased risk of disease recurrence in a panel of 57 
patients with serous ovarian carcinoma (Leskela et l., 
2010). 
Oncogenesis 
miR-200c was found to be overexpressed in a panel of 
20 serous ovarian carcinomas compared to 8 normal 
ovarian tissues by miRNA microarray analysis (Nam et 
al., 2008). Similarly, increased expression of miR-200c 
compared to normal ovary (n=15) was reported for 
serous, endometroid and clear cell ovarian carcinoma in 
a series of 69 cancer specimens. 
Expression of miR-200c was correlated with E-
Cadherin levels in 36 primary ovarian carcinomas 
(Park et al., 2008). The regulatory effect of miR-200c 
on EMT has been shown to be mediated through 
targeting of ZEB1 and ZEB2, which transcriptionally 
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repress E-Cadherin (Gregory et al., 2008; Korpal et l., 
2008; Park et al., 2008). Re-expression of miR-200c in 
aggressive ovarian cancer cell lines was shown to 
reduce their migratory capacity; however, this effect 
appears to be independent of E-Cadherin expression 
(Cochrane et al., 2010). Furthermore, forced expression 
of miR-200c has been reported to sensitize ovarian 
cancer cells to paclitaxel treatment due to 
downregulation of miR-200c target gene TUBB3 
(Cochrane et al., 2009; Cochrane et al., 2010). 
miR-200c was also shown to be downregulated in a 
subpopulation of the ovarian cancer cell line OVCAR3 




In a panel of 99 pancreatic cancer patients, high 
expression of miR-200c was associated with increased 
overall survival (Yu et al., 2010). 
Oncogenesis 
Downregulation of miR-200c and other miR-200 
family members has been observed in gemcitabine-
resistant pancreatic cancer cell lines (Li et al., 2009; Ali 
et al., 2010). miR-200c has also been suggested to have 
a stemness-inhibiting function in pancreatic cancer 
cells through targeting of stem cell factors such as 
Bmi1 (Wellner et al., 2009). 
A double-negative feedback loop between ZEB family 
transcription factors and the miR-200 family was 
shown to regulate EMT in different cell systems, 
including pancreatic cancer cells (Burk et al., 2008). 
Consistently, high expression of miR-200c was shown 
to be associated with decreased invasive behavior in a 
panel of six pancreatic cancer cell lines, and miR-200c 
expression was correlated with E-Cadherin levels in 
pancreatic cancer specimens and cell lines (Yu et al., 
2010). Overexpression of miR-200c in pancreatic 
cancer cell lines resulted in upregulation of E-Cadherin 
expression and reduced invasion but stimulated 
proliferation. 
miRNA expression profiling of various stages in a 
mouse model of multistep tumorigenesis of the 
pancreas revealed that miR-200c is downregulated in 
metastases and metastasis-like tumors (Olson et al., 
2009). Moreover, miR-200c also targets components of 
the Notch pathway, which is aberrantly activated in 
pancreatic cancer (Brabletz et al., 2011). 
Undifferentiated, aggressive pancreatic 
adenocarcinomas were shown to have higher 
expression of ZEB1 and Notch pathway components 
and lower expression of miR-200c compared to 
differentiated tumors. 
In contrast to the studies described above, which 
suggest a metastasis-suppressing function for miR-200c 
in pancreatic cancer, a comparison of 16 pancreatic 
ductal adenocarcinoma cell lines found that miR-200c 
expression was upregulated in the highly metastatic cell 
lines (Mees et al., 2010). 
Prostate cancer 
Oncogenesis 
Prostate cancer cells with EMT phenotype were found 
to have stem-cell like properties and express low levels 
of miR-200 family members (Kong et al., 2010). 
Overexpression of miR-200c reversed EMT and stem-
cell like properties, in part due to targeting of Notch-1. 
miR-200c was also shown to target the Notch ligand 
Jagged1, resulting in decreased proliferation of 
metastatic prostate cancer cells (Vallejo et al., 2011). 
Renal cancer 
Disease 
Clear cell carcinoma (CCC); Chromophobe renal cell 
carcinoma (ChCC). 
Oncogenesis 
Diagnosis. miR-200c has been found to be specifically 
expressed in chromophobe renal cell carcinoma and hs 
been suggested as one of a set of microRNAs that can 
be used to distinguish between renal cell carcinoma 
subtypes (Fridman et al., 2010). 
miR-200c was found to be significantly downregulated 
in clear cell carcinoma compared to normal kidney in a 
panel of 16 CCCs, 4 ChCCs and 6 normal kidneys both
by microarray analysis and by qRT-PCR (Nakada et al., 
2008). Furthermore, miR-200c expression was 
inversely correlated with expression of its target ne 
ZEB1 in these specimens. The downregulation of miR-
200c in CCC was also confirmed by a second study 
comparing a total of 25 clear cell carcinomas and 
matched adjacent normal tissue (Liu et al., 2010). 
Thyroid carcinoma 
Oncogenesis 
The expression of miR-200 family members, including 
miR-200c, was found to be downregulated in 
undifferentiated, aggressive anaplastic thyroid 
carcinoma compared to both normal tissue and well-
differentiated papillary and follicular thyroid 
carcinomas (Braun et al., 2010). Overexpression of the 
miR-200 family induced mesenchymal-to-epithelial 
transition and reduced invasion of ATC cells. 
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Various cancers 
 
miR-200c target genes regulate numerous processes involved in cancer development and progression. 
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